The PennZone

  • Home
  • Music
  • Entertainment
  • Marketing
  • Non-profit
  • Education
  • Technology
  • Event
  • Books

Techdow USA Announces FDA Approval of Generic Lovenox®, (Enoxaparin Sodium – Preservative Free) In Prefilled Syringes
The PennZone/10224695

Trending...
  • Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Board of Directors
  • Why Baton Rouge's Humid Climate Can Contribute to Carpenter Ant Damage — J&J Exterminating Explains How to Protect Your Home
  • LiteracyNation's 3rd Annual Indie Author Book Fair
LANGHORNE, Pa. ~ Techdow USA Inc., a vertically integrated generic injectables company, has announced the FDA approval of Enoxaparin Sodium (Preservative Free) in Prefilled Syringes for the U.S. market.

Darren Alkins, Chief Executive Officer of Techdow USA, said "We are excited to bring this critical product to institutions, retail and other networks in need of a safe, affordable and reliable source of Enoxaparin. Our U.S. and global networks will help ensure reliable Enoxaparin supply, while offering competitive pricing."

The launch of Enoxaparin will compliment Techdow USA's existing Heparin Sodium injection business which was launched in 2022. According to IQVIA Health for the 12 months ending December 2022, Enoxaparin Sodium (Preservative Free) Prefilled Syringes had US brand and generic sales of approximately $550 million.

Techdow USA is among the fastest growing companies in the US generic pharmaceutical industry specializing in the sale of generic injectable pharmaceuticals and continues to work to expand their product portfolio and pipeline to better serve patient and customer needs. To report SUSPECTED ADVERSE REACTIONS, contact Hepalink USA, Inc./Techdow USA, Inc. at 1-888-355-1375 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For more information visit www.techdowusa.com.*Lovenox® is a registered trademark of Sanofi-Aventis U.S. LLC

More on The PennZone
  • OPUS Global Data Solutions Launches Food Trader Plus, Bringing Operational Control and Deal-Level Profit Visibility to Food Brokers
  • Phinge CEO DeMaio Unveils Speech to Congress: User Data Sovereignty vs Tech Surveillance Capitalism, Asserting Foundational 2021 App-Less Patents & IP
  • Michael Maertens Hired as Century Fasteners Corp. – Chief Financial Officer
  • LATO AI Software Innovations Expedite Inspections & Repair of Parking Lots for The Pavement Group
  • Built to Last: Why BSI Is Among the Nation's Fastest-Growing Companies, and One of Its Best Places to Work

Techdow USA Inc., a growing market leader in the generic injectables industry, has announced that its product Enoxaparin Sodium (Preservative Free) in Prefilled Syringes has been approved by the FDA for use in the U.S market. Darren Alkins, Chief Executive Officer of Techdow USA expressed his excitement about bringing this critical product to institutions, retail and other networks that need a safe, affordable and reliable source of Enoxaparin with competitive pricing options available through their U.S and global networks as well as being a long term reliable resource for the marketplace .

The launch of Enoxaparin compliments Techdow USA's existing Heparin Sodium injection business which was launched in 2022 with IQVIA Health reporting US brand and generic sales for this product at approximately $550 million for the 12 months ending December 2022 .

Techdow USA is continuing its efforts to expand its product portfolio and pipeline to better serve patient and customer needs while also being one of the fastest growing companies in the US generic pharmaceutical industry specializing in selling generic injectable pharmaceuticals . To report SUSPECTED ADVERSE REACTIONS contact Hepalink USA , Inc./Techdow USA , Inc . at 1 - 888 - 355 - 1375 or FDA at 1 - 800 - FDA - 1088 or www . fda . gov / medwatch . For more information visit www . techdowusa . com * Lovenox® is a registered trademark of Sanofi - Aventis U . S . LLC
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • The World's No.1 Superstar® Enters the Occult with New Track and Cinematic Visual "Under Your Spell"
  • PricZone Launches Online Shopping Platform Offering Electronics, Gaming, and More
  • Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community
  • Lineus Medical Elevates Leadership to Accelerate Growth After Breakthrough Clinical Results
  • Gateway Center Arena Announces Duane Curry as General Manger
  • Mumbai Central Farmers Market Launches Community Collective for More Value and Connection
  • XRPPower Expands Platform Security With Enhanced Brand Protection and Official Verification Standards
  • Cuvo Health, the #1 White Label Telehealth Platform, Surpasses 300 Exclusive Providers Serving All 50 States
  • Birkdale Investments LLC Acquires Assets of Mumbai Central Farmers Market, Unveils Expanded Vision
  • RAS AP Consulting Expands Managed AP Governance™ Ecosystem, Launches Trademark Process, and Secures IFOL Speaker Invitation
  • UK Financial Ltd Makes History: Chainlink CRE Circulating Supply Verification Goes Live Across Its Complete Ecosystem Of Nine Exchange-Traded Tokens
  • International Rights Groups Raise Alarm Over Freedom of Religion and Expression in South Korea
  • The City's Most Elegant Open-Air Dinner Party Returns September 12, 2026
  • LiteracyNation's 3rd Annual Indie Author Book Fair
  • FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP)
  • Autonomous Robotics Platform Expansion as Public Market Debut is Very Close: MBody AI Corp. (N A S D A Q: MBAI)
  • Loud! OOH calls for prize draw advertising standards as £1.3bn category moves outdoors
  • Insurance for Braces Helps Make Treatment More Manageable for Pennsylvania Families
  • Black Ribbon Productions Launches With Fearless 2026 Horror Slate
  • Actor Dominic Pace Returns to Television and Film

Popular on PennZone

  • Community Partnership Brings Live Theater to 150+ Young People
  • CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
  • Martin A. Sumichrast Joins Hawkeye Systems, Inc. as Chairman of the Board
  • Philadelphia Community Invited to Unite for Praise-A-Thon Summer Concert Benefiting Cobbs Creek
  • Heritage at Manalapan Introduces Luxury Single-Family Homes with Exceptional Value in One of Monmouth County's Most Desirable Locations
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • The J. Wes Project Celebrates 11 Years of Love, Music & Inspiration
  • Stepping Off the Grid: Savista Retreat Announces New Experiential Packages in Jaipur for Travellers
  • Cogs and Marvel expands EMEA leadership team for next phase of growth
  • Allstream Energy Partners Returns as a Media Partner for the 2026 API Inspection & Mechanical Integrity Summit in San Antonio

Similar on PennZone

  • New Book Calls 'Sense of Belonging' the Missing Link in Student Success
  • KT Medical Staffing Addresses the Questions Families Forget to Ask Before Bringing Private Nursing Care Home
  • Private Autopsies Give Arizona Families Answers After Nursing Home and Care Facility Deaths
  • OPUS Global Data Solutions Launches Food Trader Plus, Bringing Operational Control and Deal-Level Profit Visibility to Food Brokers
  • Bent Danholm's The Architecture of Demand Reaches No. 2 in Amazon Real Estate Sales
  • Contracting Resources Group Named to Inc. 5000 for the Ninth Time
  • Lineus Medical Elevates Leadership to Accelerate Growth After Breakthrough Clinical Results
  • Gateway Center Arena Announces Duane Curry as General Manger
  • XRPPower Expands Platform Security With Enhanced Brand Protection and Official Verification Standards
  • Cuvo Health, the #1 White Label Telehealth Platform, Surpasses 300 Exclusive Providers Serving All 50 States
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us